Skip to main content

Alpine Immune Sciences, Inc.

ALPNDelisted May 20, 2024
Industry
Pharmaceutical Preparations
SEC CIK
0001626199

Alpine Immune Sciences, Inc. was delisted on May 20, 2024; its insiders filed their last Form 4 on May 20, 2024; 180 institutions reported holding it in 13F filings for Q1 2024, worth $2.56B in total; no superinvestor held it.

13F holders, Q4 2023

Institutional positions in Alpine Immune Sciences, Inc. as of Dec 31, 2023. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works

Institutional holders
133
+46 vs. Q3 2023
Shares held
58.9M
+19.7M (+50.3%) vs. Q3 2023
Total value
$1.12B
+$674.1M (+150.1%) vs. Q3 2023
New holders
55
62 more added
Sold out
9
10 more reduced

1 institution that held it in Q3 2023 haven't filed for Q4 2023 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.

Compare with Q3 2023: new holders, sold out and not filed yet

Holders and value by quarter

Institutions reporting ALPN on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.

Institutional holdersQ4 2023: 133 institutions
Q1 2021: 48 institutionsQ2 2021: 47 institutionsQ3 2021: 44 institutionsQ4 2021: 53 institutionsQ1 2022: 56 institutionsQ2 2022: 58 institutionsQ3 2022: 70 institutionsQ4 2022: 64 institutionsQ1 2023: 61 institutionsQ2 2023: 77 institutionsQ3 2023: 88 institutionsQ4 2023: 133 institutionsQ1 2024: 180 institutionsQ2 2024: 0 institutionsQ3 2024: 0 institutionsQ4 2024: 0 institutionsQ1 2025: 0 institutionsQ2 2025: 0 institutionsQ3 2025: 0 institutionsQ4 2025: 0 institutionsQ1 2026: 0 institutionsQ2 2026: 0 institutions
Value heldQ4 2023: $1.12B
Q1 2021: $145.0MQ2 2021: $118.5MQ3 2021: $163.5MQ4 2021: $257.1MQ1 2022: $221.8MQ2 2022: $204.4MQ3 2022: $284.0MQ4 2022: $300.8MQ1 2023: $319.4MQ2 2023: $449.3MQ3 2023: $525.8MQ4 2023: $1.12BQ1 2024: $2.56BQ2 2024: $0Q3 2024: $0Q4 2024: $0Q1 2025: $0Q2 2025: $0Q3 2025: $0Q4 2025: $0Q1 2026: $0Q2 2026: $0
Institutions holding ALPN and their total value by quarter
QuarterHoldersValue
Q2 20260$0
Q1 20260$0
Q4 20250$0
Q3 20250$0
Q2 20250$0
Q1 20250$0
Q4 20240$0
Q3 20240$0
Q2 20240$0
Q1 2024180$2.56B
Q4 2023133$1.12B
Q3 202388$525.8M
Q2 202377$449.3M
Q1 202361$319.4M
Q4 202264$300.8M
Q3 202270$284.0M
Q2 202258$204.4M
Q1 202256$221.8M
Q4 202153$257.1M
Q3 202144$163.5M
Q2 202147$118.5M
Q1 202148$145.0M

Institutions, Q4 2023

Shares, value and share of portfolio for each institution holding Alpine Immune Sciences, Inc.; share changes are against Q3 2023.

Institutions holding ALPN in Q4 2023
InstitutionSharesValue% of portfolioChange in sharesAction
Two Sigma Advisers, LP264,075$5.03M0.01%+18,000+7.3%Added
Millennium Management LLC273,066$5.20M0.00%+190,140+229.3%Added
D. E. Shaw & Co., Inc.295,542$5.63M0.01%+246,911+507.7%Added
Northern Trust Corp296,695$5.66M0.00%+26,271+9.7%Added
Charles Schwab Investment Management Inc297,452$5.67M0.00%+63,196+27.0%Added
Silverarc Capital Management, LLC297,789$5.68M1.75%+297,789New
Ally Bridge Group (NY) LLC357,271$6.81M4.90%+357,271New
Walleye Capital LLC365,940$6.97M0.10%+179,667+96.5%Added
Two Sigma Investments, LP378,413$7.21M0.02%+187,824+98.5%Added
Candriam Luxembourg S.C.A.470,000$8.96M0.06%+470,000New
Ikarian Capital, LLC487,248$9.29M2.54%+487,248New
Janus Henderson Group PLC583,239$11.1M0.01%+583,239New
Adage Capital Partners GP, L.L.C.714,590$13.6M0.03%+714,590New
Morgan Stanley718,741$13.7M0.00%+665,268+1,244.1%Added
Geode Capital Management, LLC764,347$14.6M0.00%+135,422+21.5%Added
Vivo Capital, LLC819,275$15.6M1.28%−95,638−10.5%Reduced
Citadel Advisors LLC875,257$16.7M0.02%+847,083+3,006.6%Added
Woodline Partners LP1,000,106$19.1M0.21%−38,671−3.7%Reduced
Franklin Resources Inc1,220,333$23.3M0.01%+1,220,333New
Octagon Capital Advisors LP1,241,300$23.7M3.79%+491,300+65.5%Added
State Street Corp1,390,029$26.5M0.00%+784,484+129.6%Added
Commodore Capital LP1,610,000$30.7M2.68%+285,000+21.5%Added
Price T Rowe Associates Inc1,687,278$32.2M0.00%+290,834+20.8%Added
Vanguard Group Inc2,234,767$42.6M0.00%+759,888+51.5%Added
OrbiMed Advisors LLC2,535,245$48.3M0.97%−1,546,347−37.9%Reduced
Cormorant Asset Management, LP2,550,000$48.6M2.33%+650,000+34.2%Added
BlackRock Inc.3,058,498$58.3M0.00%+706,581+30.0%Added
Frazier Life Sciences Management, L.P.3,131,008$59.7M3.19%+145,251+4.9%Added
Paradigm Biocapital Advisors LP3,176,743$60.5M2.84%+755,000+31.2%Added
Great Point Partners LLC3,703,433$70.6M12.03%+624,800+20.3%Added
Lynx1 Capital Management LP3,813,926$72.7M28.58%+1,409,312+58.6%Added
Ra Capital Management, L.P.4,909,763$93.6M1.46%+218,585+4.7%Added
Decheng Capital LLC7,083,288$135.0M37.72%+7,083,288New
Ghost Tree Capital, LLC0$00.00%−664,132−100.0%Sold out
Avidity Partners Management LP0$00.00%−657,280−100.0%Sold out
Tri Locum Partners LP0$00.00%−314,029−100.0%Sold out
Omega Fund Management, LLC0$00.00%−153,700−100.0%Sold out
Schonfeld Strategic Advisors LLC0$00.00%−90,937−100.0%Sold out
Soleus Capital Management, L.P.0$00.00%−88,073−100.0%Sold out
Moore Capital Management, LP0$00.00%−13,744−100.0%Sold out
SG Americas Securities, LLC0$00.00%−9,927−100.0%Sold out
Dorsey Wright & Associates0$00.00%−2,273−100.0%Sold out
Decheng Capital Management III (Cayman), LLC––––Not filed